-
Something wrong with this record ?
Serological survey of measles immunity in the Czech Republic, 2013
H. Tomášková, H. Zelená, A. Kloudová, I. Tomášek
Language English Country Czech Republic
Document type Journal Article
Digital library NLK
Source
NLK
Free Medical Journals
from 2004
ProQuest Central
from 2009-03-01 to 6 months ago
Medline Complete (EBSCOhost)
from 2006-03-01 to 6 months ago
Nursing & Allied Health Database (ProQuest)
from 2009-03-01 to 6 months ago
Health & Medicine (ProQuest)
from 2009-03-01 to 6 months ago
Public Health Database (ProQuest)
from 2009-03-01 to 6 months ago
ROAD: Directory of Open Access Scholarly Resources
from 1993
PubMed
29684293
DOI
10.21101/cejph.a5251
Knihovny.cz E-resources
- MeSH
- Child MeSH
- Adult MeSH
- Infant MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Immunization Schedule MeSH
- Child, Preschool MeSH
- Prevalence MeSH
- Antibodies, Viral blood MeSH
- Seroepidemiologic Studies MeSH
- Measles epidemiology immunology prevention & control MeSH
- Measles-Mumps-Rubella Vaccine administration & dosage MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Infant MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
OBJECTIVES: The aim of the serological survey of measles was to obtain information on the prevalence of antibodies against measles and to verify the effectiveness of vaccination in the Czech population in order to protect public health. METHODS: The serological survey was carried out in the Czech Republic in 2013. Antibodies against measles were tested in 3,111 serum samples of participants aged 1-64 years. Serum samples were tested for the presence of immunoglobulin G (IgG) antibodies by enzyme immunoassay (EIA). The vaccination status assessment was based on the medical documentation. Seroprevalence differences were evaluated by sex and age using the Pearson's χ2 test at 5% significance level. RESULTS: The overall seroprevalence reached 93.0% (2,893/3,111) (95% CI 92.0-93.9). No statistically significant difference was found between men and women (p=0.724). A lower seroprevalence was identified in the first age group (1-year old children) 62% (62/100), as the vaccination has not yet been completed in this age group. The second lowest seroprevalence 80.4% (160/199) was identified in the age group of 35-44 years. The highest seroprevalence 97.7% (387/396) (95% CI 95.7-99.0) was in the population with naturally-induced immunity (age above 45 years). In the individuals with two doses seroprevalence reached 94.1% (2,081/2,212) (95% CI 93.0-95.0). The level of IgG antibodies decreased in persons above 7 years of age. CONCLUSIONS: Based on the results of the serological survey carried out in 2013 in the Czech Republic, it has been decided to postpone the second MMR (measles, mumps and rubella) dose to the age of 5-6 years.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19003028
- 003
- CZ-PrNML
- 005
- 20190123095416.0
- 007
- ta
- 008
- 190116s2018 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21101/cejph.a5251 $2 doi
- 035 __
- $a (PubMed)29684293
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Tomášková, Hana $u Public Health Institute Ostrava, Ostrava, Czech Republic. Department of Epidemiology and Public Health, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. $7 pna2008424773
- 245 10
- $a Serological survey of measles immunity in the Czech Republic, 2013 / $c H. Tomášková, H. Zelená, A. Kloudová, I. Tomášek
- 520 9_
- $a OBJECTIVES: The aim of the serological survey of measles was to obtain information on the prevalence of antibodies against measles and to verify the effectiveness of vaccination in the Czech population in order to protect public health. METHODS: The serological survey was carried out in the Czech Republic in 2013. Antibodies against measles were tested in 3,111 serum samples of participants aged 1-64 years. Serum samples were tested for the presence of immunoglobulin G (IgG) antibodies by enzyme immunoassay (EIA). The vaccination status assessment was based on the medical documentation. Seroprevalence differences were evaluated by sex and age using the Pearson's χ2 test at 5% significance level. RESULTS: The overall seroprevalence reached 93.0% (2,893/3,111) (95% CI 92.0-93.9). No statistically significant difference was found between men and women (p=0.724). A lower seroprevalence was identified in the first age group (1-year old children) 62% (62/100), as the vaccination has not yet been completed in this age group. The second lowest seroprevalence 80.4% (160/199) was identified in the age group of 35-44 years. The highest seroprevalence 97.7% (387/396) (95% CI 95.7-99.0) was in the population with naturally-induced immunity (age above 45 years). In the individuals with two doses seroprevalence reached 94.1% (2,081/2,212) (95% CI 93.0-95.0). The level of IgG antibodies decreased in persons above 7 years of age. CONCLUSIONS: Based on the results of the serological survey carried out in 2013 in the Czech Republic, it has been decided to postpone the second MMR (measles, mumps and rubella) dose to the age of 5-6 years.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a protilátky virové $x krev $7 D000914
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a očkovací schéma $7 D007115
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a spalničky $x epidemiologie $x imunologie $x prevence a kontrola $7 D008457
- 650 _2
- $a vakcína proti spalničkám, příušnicím a zarděnkám $x aplikace a dávkování $7 D022542
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a séroepidemiologické studie $7 D016036
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zelená, Hana $u Public Health Institute Ostrava, Ostrava, Czech Republic. $7 xx0096746
- 700 1_
- $a Kloudová, Alena $u Public Health Institute Ostrava, Ostrava, Czech Republic. $7 xx0081740
- 700 1_
- $a Tomášek, Ivan $u Public Health Institute Ostrava, Ostrava, Czech Republic. $7 xx0231593
- 773 0_
- $w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 26, č. 1 (2018), s. 22-27
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29684293 $y Pubmed
- 910 __
- $a ABA008 $b B 1829 $c 562 $y a $z 0
- 990 __
- $a 20190116 $b ABA008
- 991 __
- $a 20190122102539 $b ABA008
- 999 __
- $a ok $b bmc $g 1370095 $s 1041190
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 26 $c 1 $d 22-27 $i 1210-7778 $m Central European Journal of Public Health $n Cent. Eur. J. Public Health $x MED00001083
- LZP __
- $b NLK118 $a Pubmed-20190116